Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5125]
News [14834]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
Circulating tumour DNA used to predict disease recurrence for early triple...
Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...
Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
19 Dec 2019
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for...
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )
18 Dec 2019
Predicting disease recurrence in patients with early triple-negative breast...
Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...
Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
18 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
18 Dec 2019
LYRA: Maintenance therapy with daratumumab improves depth of response and...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
17 Dec 2019
KRd consolidation in MM patients with a positive PET-CT after standard first...
Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway
KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )
17 Dec 2019
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center...
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )
17 Dec 2019
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Dec 2019
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory...
Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )
17 Dec 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation